Related Experiment Videos
Peripheral neuropathy after cis-platinum (II) (DDP) therapy
Archives of Physical Medicine and Rehabilitation
|June 1, 1980
Summary
Malignant fibrous histiocytoma treatment led to peripheral neuropathy. Cis-diamminedichloplatinum (II) (DDP) therapy caused nerve damage, but symptoms improved after treatment cessation.
Area of Science:
- Oncology
- Neurology
- Pharmacology
Background:
- A 56-year-old male patient was diagnosed with malignant fibrous histiocytoma in the left antecubital space.
- Initial treatment involved local resection, radiation, and chemotherapy (Adriamycin, Levamisole), achieving disease resolution.
Observation:
- Recurrence of the tumor occurred in January 1977, with electrophysiologic studies indicating median nerve demyelination.
- Cis-diamminedichloplatinum (II) (DDP) therapy was initiated in July 1977.
Findings:
- Five months into DDP therapy, the patient developed peripheral neuropathy with paresthesias in hands and feet.
- Nerve conduction studies confirmed mixed sensorimotor peripheral neuropathy, worsening with continued DDP treatment.
- Following DDP cessation, nerve conduction studies showed significant improvement over 11 months, approaching normal values.
Implications:
- This case highlights the neurotoxic potential of Cis-diamminedichloplatinum (II) (DDP) in cancer patients.
- Monitoring for peripheral neuropathy is crucial during DDP treatment.
- Reversibility of DDP-induced neuropathy suggests potential for recovery after treatment discontinuation.